Business Context and Reporting Period
This Form 8-K filing by Sonoma Pharmaceuticals, Inc. (Delaware) was submitted on January 4, 2019. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock price compliance rather than financial performance metrics.
Material Changes
- Listing Deficiency: The company failed to maintain the minimum bid price of $1.00 per share for its common stock for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Compliance Period: Nasdaq granted the company a 180-calendar-day period (until July 3, 2019) to regain compliance.
- Current Status: The notice has no immediate effect on the listing or trading of the company's common stock.
Outlook, Risks, and Contingencies
- Regaining Compliance: The company may regain compliance at any time during the period if the bid price remains at least $1.00 for ten consecutive business days.
- Delisting Risk: There is no assurance the company will regain compliance. Failure to do so may result in delisting unless the company qualifies for an additional 180-day period.
- Extension Requirements: To qualify for an extension, the company must meet the market value of publicly held shares requirement and all other initial listing standards (excluding bid price). This may require effecting a reverse stock split.
- Forward-Looking Statements: The filing includes standard disclaimers that actual outcomes may differ materially from expectations due to risks and uncertainties.
Investor Verification Checklist
- Verify the current trading price of Sonoma Pharmaceuticals common stock to assess proximity to the $1.00 threshold.
- Monitor the company's stock price performance over the next 10 consecutive business days to determine if immediate compliance is achieved.
- Review upcoming filings for announcements regarding a potential reverse stock split if the bid price remains below $1.00.
- Check the company's market value of publicly held shares to ensure eligibility for a potential second compliance period.